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Objectives: We examined the data reported in studies for diagnostic purposes and to discuss whether
their intended use could be extended to triage, as rule-in or rule-out tests to select individuals who
should undergo further conﬁrmatory tests.
Methods: We searched Scopus, PubMed and Web of Science with the terms ‘acute phase proteins,’ ‘IP-10,’
‘tuberculosis,’ ‘screening’ and ‘diagnosis,’ extracted the sensitivity and speciﬁcity of the biomarkers and
explored methodologic differences to explain performance variations. Summary estimates were calcu-
lated using random-effects models for overall pooled accuracy. The hierarchical summary receiver
operating characteristic model was used for meta-analysis.
Results: We identiﬁed 14, four and one studies for C-reactive protein (CRP), interferon geinduced protein
10 (IP-10) and alpha-1-acid glycoprotein (AGP). The pooled CRP sensitivity/speciﬁcity (95% conﬁdence
interval) was 89% (80e96) and 57% (36e65). Sensitivity/speciﬁcity were higher in high-tuberculosis-
burden countries (90%/64%), HIV-infected individuals (91%/61%) and community-based studies (90%/
62%). IP-10 sensitivity/speciﬁcity in TB vs. non-TB studies was 85%/63% and in TB and HIV coinfected vs.
other lung conditions 94%/21%. However, IP-10 studies included diverse populations and a high risk of
bias, resulting in very low-quality evidence. AGP had 86%/93% sensitivity/speciﬁcity.
Conclusions: Few studies have evaluated CRP, IP-10 and AGP for the triage of symptomatic patients. Their
high sensitivity and moderate speciﬁcity warrant further prospective studies exploring whether their
combined use could optimize performance. V.S. Santos, Clin Microbiol Infect 2019;25:169
© 2018 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).chool of Tropical Medicine,
vas).
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB) causes an estimated 1.7 million deaths and
10.4 million incident cases per year [1]. Despite its public health
burden, nearly one third of the estimated cases are missed by na-
tional surveillance systems, suggesting that many cases fail to reachof Clinical Microbiology and Infectious Diseases. This is an open access article under
V.S. Santos et al. / Clinical Microbiology and Infection 25 (2019) 169e177170the health services. TB mortality is higher in patients with a late
diagnosis, advanced disease stages and coinfection with HIV, and
strategies which increase case detection and reach an early diag-
nosis are integral to the global strategy for the control of TB [2].
One of the major problems for the management of TB is the
inefﬁciency of the diagnostic cascade. Diagnostic investigations are
usually triggered after a patient has had cough for two or more
weeks; however, the tests used are unsuitable for rapid and large-
scale screening. The most frequently used tests, smear microscopy
and Xpert MTB/RIF (Mycobacterium tuberculosis complex/resistance
to rifampin), are highly speciﬁc. However, smear microscopy has
low sensitivity and is technically unsuitable as a screening tool, and
Xpert MTB/RIF and X-rays require an infrastructure that is rarely
available at peripheral diagnostic centres. It is recognized that
diagnostic algorithms could be improved with the use of triage
tests that select patients requiring further conﬁrmatory tests and
exclude patients unlikely to have TB [3]. The World Health Orga-
nization has included, among the high-priority target product
proﬁles for TB diagnosis, a nonesputum-based triage test, which,
under ideal conditions, would require sensitivity 95% and speci-
ﬁcity >75% [4]. However, early promising prototypes for triage,
such as a b-lactamase C assay [5], failed to reach the production
stages, and the pipeline for these tests has very few candidates [6].
Serum levels of acute phase proteins (APPs) and cytokines are
increased in individuals with TB. Among these, C-reactive protein
(CRP) is often used in clinical practise as an adjuvant test for
diagnosis (especially in children) [7], and interferon geinduced
protein 10 (IP-10) may have potential to monitor treatment re-
sponses to anti-TB therapy [7e9]. Despite their frequent use for
diagnosis, they are rarely used as triage tests, and their use for these
different purposes require different performance characteristics.
Cutoffs or thresholds for a test for diagnostic purposes are deﬁned
to achieve a high accuracy and use the best combination of sensi-
tivity and speciﬁcity, whereas triage tests require high sensitivity in
order to identify as many cases as possible, often at the expense of
lower speciﬁcity.
There is renewed interest to explore whether APPs and cyto-
kines could be used as triage tests for TB. As few studies have
considered using APPs and IP-10 for screening purposes, we
examined the data reported in studies for diagnostic purposes and
assessed whether their intended use could be extended to triage, as
rule-in or rule-out tests to select individuals who should undergo
further conﬁrmatory tests.
Methods
This study was conducted following the Cochrane Collabora-
tion's Diagnosis Test Accuracy Working Group protocol. Institu-
tional review board approval and informed consent were not
required for this systematic review and meta-analysis. A study
protocol was designed a priori and was registered in the PROSPERO
database (registration CRD42018087015). We reported our ﬁndings
according to Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) guidelines.
Search strategy and selection criteria
We performed a systematic review using Scopus, PubMed and
Web of Science databases to identify studies published without
language restriction up to 14 October 2017. We used the search
terms ‘acute phase proteins,’ ‘IP-10,’ ‘tuberculosis,’ ‘screening,’
‘diagnosis’ and related terms. The full search strategy is described in
the Supplementary Appendix. Two independent review authors
(VSS and KK) screened the title and abstract for relevance, and a
third review author (LEC) was consulted to resolve disagreements.Articles considered to have original material were obtained and
assessed in detail, and the references cited in these publications
were searched to identify further publications.
We included studies that met the following conditions. First, the
study used quantitative laboratory-based and/or point-of-care as-
says tomeasure levels of at least oneofAPP (a-1-antiechymotrypsin,
a-1-antietrypsin, a-2-macroglobulin, alpha-1-acid glycoprotein
(AGP), ceruloplasmin, complement factors, CRP, factor VIII, ferritin,
ﬁbrinogen, haptoglobin, hepcidin, mannan-binding lectin, oroso-
mucoid, plasminogen activator inhibitor 1, prothrombin, serum
amyloid A, serum amyloid P component and vonWillebrand factor)
or unstimulated IP-10 as an index test.We included unstimulated IP-
10 because there is an extensive number of publications reporting its
potential use for diagnosis. Second, the study enroled symptomatic
patients suspected of having active pulmonary TB, of whom a pro-
portion was conﬁrmed as having pulmonary TB and another pro-
portion as having other lung disease. Third, patients had conﬁrmed
pulmonary TB based on solid and/or liquid sputum M. tuberculosis
culture as the reference standard. Finally, it reported cases in abso-
lute numbers of true-positive, false-positive, false-negative and true-
negative results or these data were derivable from the published
results. Articles were included regardless of age (adults or children)
or whether subjects had coinfections (e.g. HIV).
We excluded studies that only reported stimulated IP-10 values,
but the authors of these studies were asked to provide the non-
stimulated baseline results if available (e.g. the nil values of the
QuantiFERON assay) to prepare additional receiver operating
curves for meta-analysis. Studies that focused on latent
M. tuberculosis infections, those that tested patients after initiation
of treatment and those that used samples other than blood (e.g.
pulmonary biopsy samples or pleural exudates) as well as
caseecontrol studies were excluded.
Data extraction and bias assessment
We predeﬁned tables for data extraction, which were piloted
in ten articles. The information extracted included author, coun-
try, study design, clinical setting (hospital or community)
participant characteristics, case deﬁnition for TB diagnosis,
markers included, method of detection and the threshold used for
each marker. We extracted the absolute numbers of true-positive,
false-positive, false-negative and true-negative test results from
the paper or through (re)calculations of the sensitivity and
speciﬁcity based on the authors' diagnostic classiﬁcation of the
participants and sample size of the study. If a study presented
multiple cutoff values for an index test and as consequence re-
ported multiple pairs of sensitivity and speciﬁcity, the data with
the best combined estimates for sensitivity and speciﬁcity were
extracted. Countries were classiﬁed according to the World
Health Organization burden of TB classiﬁcation [1] to describe the
epidemiologic context. The quality of studies and the risk of bias
were assessed by two independent reviewer authors using the
QUADAS-2 guidelines (Supplementary Materials). We used Rev-
Man 5.3 software (Cochrane Collaboration) to generate the graphs
on the risk of bias.
Statistical analysis
We used the sensitivity and speciﬁcity of the markers reported
by the author or (re)calculated them from the data presented. For
diagnostic performance of CRP, we ﬁtted the hierarchical summary
receiver operating characteristic (HSROC) model proposed by Rut-
ter and Gatsonis [10], which takes into account correlation between
sensitivity and speciﬁcity across studies while also allowing for
variation in test performance among studies through the inclusion
V.S. Santos et al. / Clinical Microbiology and Infection 25 (2019) 169e177 171of random effects. We expected that the methods for measuring the
markers and the cutoffs would vary across studies and thus
investigated potential methodologic and assay differences to
interpret variations in performance. An exploratory analysis to
investigate potential factors of heterogeneity was performed by
visual inspection of HSROC curves. Metaregression was conducted
by adding these factors as covariates to the hierarchical model [11].
The characteristics explored were the World Health Organization
TB burden classiﬁcation of the country where the study took place
(high burden vs. others), HIV status (positive vs. negative), clinical
settings (hospitalized vs. community) and method for CRP quan-
tiﬁcation. Publication bias was examined using the effective sample
size funnel plot and associated regression test of asymmetry
described by Deeks et al. [12].Fig. 1. Flow diagram oFor IP-10, because few studies were available, the diagnostic
performance was analysed by modelling the trade-off between
sensitivity and speciﬁcity using the Moses summary receiver
operating characteristic regression [13,14].
For all analyses, two-sided p <0.05 values were considered
statistically signiﬁcant. Statistical analyses were performed by the R
2.10.13 statistical programming language (R Core Team, 2013) and
Stata 14 (StataCorp).
Results
The search strategy identiﬁed 891 records. After screening titles
and abstracts, 104 full-text articles were assessed for eligibility and
19 were included (Fig. 1). CRP was reported in 14 studies [15e28],f study selection.
V.S. Santos et al. / Clinical Microbiology and Infection 25 (2019) 169e177172IP-10 in four [29e32] and AGP [33] in one. Table 1 summarizes the
main characteristics of each study.C-reactive protein
Six of the 14 studies reporting CRP sensitivity and speciﬁcity
included only HIV-infected [16,19,24,26e28], four only HIV-
uninfected [17,21,23,25] and two both HIV-infected and HIV-
uninfected [20,22] patients; in two studies the HIV status was not
described [15,18]. Nine studies were conducted in high-TB-burden
countries [15,16,20,22,24e28]. Nine studies enroled patients in
community settings [15,17,18,22,24e28] and ﬁve enroled hospital-
ized patients [16,19e21,23]. All studies focused on adults. Most
studies used a 10 mg/dL cutoff point (Table 1).
The quality of the studies and the risk of bias are shown
Supplementary Figs. S1 and S2. The QUADAS-2 tool showed that the
studies that enroled patients in the community had a lower risk of
bias than studies enrolling hospitalized patients. Most studies
enrolling community individuals were designed to evaluate the
diagnostic accuracy of CRP for TB and enroled a representative
spectrum of patients, whereas hospital studies did not provide
sufﬁcient information to determine the patient selection method
and had unclear blinding for the interpretation of results, which are
potential sources of bias.
The overall (95% conﬁdence interval (CI)) pooled sensitivity of
CRP was 89% (80e96) with a pooled (95% CI) speciﬁcity of 57%
(36e65) (Table 2). The positive and negative likelihood ratios (95%
CI) were 1.91 (1.42e2.56) and 0.21 (0.10e0.43), respectively
(Supplementary Tables S1 and S2). The summary diagnostic odds
ratio (95% CI) was 8.27 (3.40e20.00) (Supplementary Table S3). The
HSROC curve for CRP is shown in Fig. 2. Table 3 describes the
subgroup analysis. CRP had a higher pooled sensitivity and speci-
ﬁcity (95% CI) in countries with high TB burden (90% (82e92) and
64% (53e75)), in HIV-infected patients (91% (85e93) and 61%
(32e71)) and in community patients (90% (85e93) and 62%
(51e73), respectively).
To investigate the potential sources for heterogeneity, we con-
ducted a metaregression analysis using the country TB burden, HIV
status, clinical settings and CRP assays. Of these, the most impor-
tant source of heterogeneity was the clinical setting (Table 4). We
also explored the performance for CRP among HIV-infected pa-
tients from high-TB-burden countries. The pooled (95% CI) sensi-
tivity for this group was 92% (89e94), with a pooled (95% CI)
speciﬁcity of 66% (64e68).
No publication bias and high symmetry of the included studies
were proved by Deeks's funnel plot asymmetry test (p 0.73; Fig. 3).IP-10
Unstimulated IP-10 values were obtained from four studies
[29e32] (Table 1). One study included HIV-uninfected individuals
[29], two included both HIV-uninfected and HIV-infected patients
[30,32] and in one the HIV status was unknown [31]. Three studies
[29e31] were conducted in adults and only one in children [32]. All
studies used culture-positive sputum samples as the reference
standard for the conﬁrmation of cases. There was a wide variation
in the kits and thresholds used, andmany studies did not report the
cutoffs selected, which precluded further analysis.
Most of the studies did not enrol a representative spectrum of
patients or failed to provide satisfactory information to determine
the patient selection methods. Furthermore, the unblinded inter-
pretation of results, the lack of a prespeciﬁed cutoff thresholds and
the different assays used were common sources of potential bias
(Supplementary Figs. S6 and S7).Because the studies included a wide range of populations (often
without matched groups), it was not possible to estimate pooled
sensitivity and speciﬁcity across the studies. The performance of
unstimulated IP-10 test is thus presented for each group in Table 5.
The pooled (95% CI) sensitivity and speciﬁcity to diagnose TB was
85% (77e92) and 63% (54e71), respectively. Studies comparing
patients with TB and HIV coinfection and patients with other lung
diseases had an estimated sensitivity (95% CI) of 94% (80e99) and
speciﬁcity of 21% (14e29). Summary diagnostic odds ratios (95% CI)
were as follows: TB vs. non-TB, 13.19 (2.28e76.27); TB HIV positive
vs. non-TB HIV positive, 3.11 (0.79e12.26).Alpha-1-acid glycoprotein
Only one study [33] reporting data for AGP was included. This
study enroled 21 patients with TB and 27 patients with bacterial
pneumonia. The sensitivity and speciﬁcity (95% CI) were 86%
(64e95) and 93% (75e98), respectively.
There were no studies describing the combined use of CRP with
IP-10 or AGP to explore whether using two or more of these
markers would result in a higher sensitivity.Discussion
It is estimated that nearly 4.1 million TB cases are missed
annually worldwide [1], and increasing the accessibility of diag-
nostic and treatment services is essential for its effective control.
Although sensitive and speciﬁc molecular diagnostics, such as
Xpert MTB/RIF, are now available, these tests require well-
established laboratory facilities and are relatively expensive for
low-income countries. Although national programmes are
attempting to increase the use of Xpert MTB/RIF as the ﬁrst test for
diagnosis of presumptive TB, patients attending primary health
centres are mostly screened using smear microscopy or need to
travel or have their samples transported to laboratories with Xpert
MTB/RIF facilities. The goal of an accessible and efﬁcient quality
diagnosis therefore remains elusive and is one of the largest bar-
riers for TB control.
Improved diagnostic algorithms able to triage patients to select
individuals with a high or low probability of TB could optimize the
use of limited resources of national programmes. These approaches
should be able to identify (rule in) individuals with a high risk of TB
and rule out those who, despite their symptoms, have a low like-
lihood of TB. Triage approaches also need to be simple and rapid,
without the need of complex platforms to facilitate implementa-
tion in low-resource settings.
Here we reviewed the potential of established APPs currently
used as adjunct assays for the diagnosis of TB. APPs are proteins
whose plasma concentrations increase or decrease rapidly as an
innate response to injury or local inﬂammation. CRP, for example,
binds to bacterial and fungal cell walls and to phosphocholine in
the surface of damaged human cells, and a high concentration
suggests the presence of bacterial infections. Although their stim-
ulation in response to a wide range of inﬂammatory processes
would result in a low speciﬁcity, their high sensitivity and the
maintenance of response integrity, even in individuals of young age
or immunodeﬁcient as a result of severe malnutrition or HIV, have
resulted in their frequent use for the diagnosis and management of
infection. Paradoxically, although APPs are included in many
diagnostic algorithms for TB, especially in children, these markers
are usually used in parallel with other tests, and testing is rarely
reported in a stepwise cascade for triage. This is a major limitation,
as markers used for diagnosis are used in parallel with other tests,
while screening tests are usually cascaded, with an emphasis on
Table 1
Characteristic of included studies
Topic Study Country Study design Status HIV Setting Study subjects Tuberculosis deﬁnition Non-TB deﬁnition Detection method Threshold
Alpha-1-acid
glycoprotein
Fassbender
(1995) [33]
Germany Cross-sectional Unknown Community 21 conﬁrmed TB, 27
non-TB and 36 healthy
controls
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
Immunoelect
-rophoresis
(immunoafﬁnity)
Not
provided
C-reactive
protein
Lin (1986) [15] China Cross-sectional Unknown Community 18 conﬁrmed TB, 26
non-TB, 12 healed TB
and 31 healthy controls
Conﬁrmed TB based on clinical features, X-ray
of chest, smear or culture from sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
Nephelometry 7 mg/mL
Wilson (2006) [16] South Africa Cohort Positive Hospital 59 conﬁrmed TB and 15
non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: adults who were initially
suspected of active TB, but who ended up had
other disease
Immunoturbidimetry 10 mg/L
Choi (2007) [17] South Korea Cross-sectional Negative Community 46 conﬁrmed TB and 67
non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
Immunoturbidimetry 11.2 mg/L
Kang (2009) [18] South Korea Prospective Unknown Community 30 conﬁrmed TB and 57
non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
Immunoturbidimetry 12.5 mg/L
Sage (2010) [19] United
Kingdom
Prospective Positive Hospital 28 conﬁrmed TB and
219 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
ELISA 10 mg/L
Bandyopadhyay
(2011) [20]
India Cohort Negative/
positive
Hospital 9 conﬁrmed TB and 43
non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
Immunoturbidimetry 10 mg/L
Lee (2011) [21] South Korea Prospective Negative Hospital 82 conﬁrmed TB and
190 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
Immunoturbidimetry 10 mg/L
Wilson (2011) [22] South Africa Prospective Negative/
positive
Community 135 conﬁrmed TB and
115 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: adults who were initially
suspected of active TB, but who ended up had
other disease
immunoturbidimetry/
spectrophotometry
10 mg/L
Cho (2012) [23] South Korea Prospective Negative Hospital 40 conﬁrmed TB and 33
non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
Immunoturbidimetry 10 mg/L
Lawn (2013) [24] South Africa Cohort Positive Community 81 conﬁrmed TB and
415 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
ELISA 5 mg/L
Niu (2013) [25] China Cross-sectional Negative Community 78 conﬁrmed TB and
113 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
immune scatter
turbidimetry
15.2 mg/mL
Drain (2014) [26] South Africa Prospective Positive Community 45 conﬁrmed TB and 47
non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up not having
TB
Immunometric
semi-quantitative
assay/
spectrophotometry
8 mg/L
Yoon (2014) [27] Uganda Prospective Positive Community 27 conﬁrmed TB and
244 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up not having
TB
ELISA 10 mg/L
Yoon (2017) [28] Uganda Prospective Positive Community 163 conﬁrmed TB and
1014 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up not having
TB
ELISA 10 mg/L
IP-10 Hong (2012) [29] South Korea Cross-sectional Negative Hospital/
community
46 conﬁrmed TB, 22
LTBI and 32 health
controls
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
ELISA 119 pg/mL
Vanini (2012) [30] Italy Prospective Negative/
positive
Community 58 conﬁrmed TB and
137 non-TB patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of PTB, but who ended up had other
disease
ELISA Not
provided
Yang (2014) [31] China Cross-sectional Unknown Hospital/
community
123 conﬁrmed TB
patients, 91 non-TB
patients, 33 LTBI
patients and 36 health
controls
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick adults who were initially
suspected of active TB, but who ended up had
other disease
ELISA Not
provided
Petrone (2015) [32] Uganda Cross-sectional Negative/
positive
Hospital/
community
32 conﬁrmed TB
patients, 79 non-TB
patients
Conﬁrmed TB based on positive culture from
sputum
Non-TB patients: sick children who were
initially suspected of PTB, but who ended up
had other disease
ELISA 209.1 pg/mL
ELISA, enzyme-linked immunosorbent assay; IP-10, interferon geinduced protein 10; LTBI, latent tuberculosis infection; PTB, pulmonary tuberculosis; TB, tuberculosis.
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Table 2
Diagnostic performance of C-reactive protein for diagnosis of tuberculosis
Source Test result (n) Sensitivity,
% (95% CI)
Speciﬁcity,
% (95% CI)
Truly positive Falsely positive Falsely negative Truly negative
Lin (1986) [15] 15 6 3 20 89 (65e99) 77 (57e91)
Wilson (2006) [16] 57 10 2 5 97 (88e100) 33 (12e62)
Choi (2007) [17] 44 39 2 28 96 (85e99) 42 (30e54)
Kang (2009) [18] 30 28 0 29 100 (88e100) 51 (37e64)
Sage (2010) [19] 25 171 3 48 89 (72e98) 22 (17e28)
Bandyopadhyay (2011) [20] 5 14 4 29 56 (21e86) 67 (51e81)
Lee (2011) [21] 67 175 15 15 82 (72e89) 8 (4e13)
Wilson (2011) [22] 128 27 7 88 95 (90e98) 77 (68e84)
Cho (2012) [23] 23 20 17 13 58 (41e73) 39 (23e58)
Lawn (2013) [24] 73 233 8 182 90 (81e96) 44 (39e49)
Niu (2013) [25] 64 14 14 21 82 (72e90) 60 (42e76)
Drain (2014) [26] 44 22 1 26 98 (88e100) 54 (39e69)
Yoon (2014) [27] 22 47 5 197 81 (62e94) 81 (75e85)
Yoon (2017) [28] 145 283 18 731 89 (83e93) 72 (69e75)
Summary estimates d d d d 89 (80e96) 57 (36e65)
CI, conﬁdence interval.
V.S. Santos et al. / Clinical Microbiology and Infection 25 (2019) 169e177174high sensitivity for selection of patients who should undergo more
speciﬁc tests for conﬁrmation.
The screening of TB among HIV-infected individuals is also
particularly challenging. A recent systematic review of CRP for the
screening of TB in patients with HIV, however, reported unex-
pectedly good results in this high-risk group [34].
Furthermore, although many studies have investigated IP-10
expression as a speciﬁc response to the in vitro stimulation of
white blood cells to speciﬁc TB antigens, few studies have reported
its use in its steady, unstimulated concentrations. Altered serum
and/or tissue expression of IP-10 has been associated with in-
ﬂammatory diseases, including organ-speciﬁc or systemic auto-
immune diseases [35], neurologic disorders [36], vascular diseases
[37,38] and viral and bacterial infections [39]. One previous meta-Fig. 2. Diagnostic accuracy of C-reactive protein test.analysis [40] reported a pooled sensitivity and speciﬁcity of 73%
and 82% for the diagnosis of TB. However, this study included data
of both stimulated and unstimulated IP-10 in patients with pleural
effusions and compared patients with TB and healthy controls,
which limited its interpretation. In the current study, we focused on
nonstimulated (in the absence of in vitro TB antigens) IP-10 in pa-
tients with pulmonary TB and requested data sets from in-
vestigators to conduct a reanalysis with a triage perspective.
Although the number of studies is small, CRP and IP-10 seem to
have high sensitivity and moderate speciﬁcity as triage markers in
patients with symptoms suggestive of active TB. Our data resulted
in a CRP pooled sensitivity and speciﬁcity of 89% and 57%, while the
pooled sensitivity and speciﬁcity for IP-10 were 85% and 63%.
Despite their low/moderate speciﬁcity, these performances would
make them strong candidates for triage because although theymiss
the target product proﬁles, their performance could potentially be
improved by calculating optimal screening cutoffs in prospectively
enroled patients. Several semiquantitative CRP tests are also
available in the market, and their use as point-of-care devices for
screening would increase the capacity of the health services to
diagnose larger number of patients. IP-10 studies in turn were
judged to have a high risk of bias and high concern about appli-
cability. Furthermore, the IP-10 studies included were considered
to have a high risk of bias, and thus the quality of evidence is very
low at this stage.
Our ﬁndings therefore should be treated with caution as we
faced important limitations. As expected, the performance of the
markers varied with the burden of TB across settings, with a higher
sensitivity and speciﬁcity in high-burden countries. The higher
sensitivity in these settings may reﬂect the late presentation of
patients to health services and the higher frequency of comorbid-
ities, such as HIV, malaria and bacterial coinfections. The higher
speciﬁcity may reﬂect the location used to enrol study participants,
as most studies were based on TB diagnostic services, where the
proportion of patients with TB would be higher than in general
clinical services. Some studies also did not provide sufﬁcient in-
formation to determine the patient selection method, with unclear
blinding, and some studies used inappropriate patient exclusions
with potential to introduce bias. Furthermore, although there was
no limitation for patient age in the search, most the articles limited
their analyses to adults, which ﬁxed the interpretations of our
ﬁndings to this age group. As much as possible, data included
comparisons between patients with and without a diagnosis of TB.
Our ﬁndings therefore reﬂect the investigator-selected cutoffs,
usually decided retrospectively by observing the data, which
Table 3
Subgroup analysis for diagnosis performance of CRP for diagnosis of TB
Subgroup No. of studies Sensitivity, % (95% CI) Speciﬁcity, % (95% CI)
TB burden
High-burden countries 9 90 (82e92) 64 (53e75)
Other countries 5 86 (69e81) 28 (15e48)
HIV status
Unknown 2 90 (54e99) 63 (36e85)
Infected 6 91 (85e93) 61 (32e71)
Uninfected 4 81 (65e90) 32 (12e63)
Uninfected/infected 2 83 (27e98) 73 (65e81)
Clinical setting
Community 9 90 (85e93) 62 (51e73)
Hospital 5 80 (61e91) 51 (37e64)
CRP quantiﬁcation method
Nephelometry 1 83 (59e95) 77 (57e89)
Immunoturbidimetry 9 88 (78e94) 46 (29e65)
ELISA 4 88 (84e91) 55 (31e77)
CI, conﬁdence interval, CRP, C-reactive protein, ELISA, enzyme-linked immunosorbent assay, TB, tuberculosis.
Table 4
Metaregression analysis for potential sources of heterogeneity
Variable Sensitivity Speciﬁcity
Coefﬁcient (95% CI) Standard error p Coefﬁcient (95% CI) Standard error p
WHO TB burden
High-burden country Reference
Other country 1.686 (0.140 to 3.232) 0.789 0.033 0.750 (2.104 to 0.605) 0.691 0.278
HIV status
Unknown Reference
Uninfected 1.020 (4.171 to 2.132) 1.608 0.526 0.366 (1.841 to 1.110) 0.753 0.627
Infected 1.360 (2.414 to 5.134) 1.926 0.480 0.617 (2.641 to 1.407) 1.033 0.550
Uninfected/infected 0.127 (4.428 to 4.173) 2.194 0.954 1.149 (1.748 to 4.046) 1.478 0.437
Clinical setting
Community Reference
Hospital 2.074 (3.574 to 0.574) 0.765 0.007 1.205 (2.455 to 0.045) 0.638 0.059
Community/hospital 0.434 (2.890 to 2.022) 1.253 0.729 0.860 (2.635 to 0.915) 0.906 0.342
CRP quantiﬁcation method
Nephelometry Reference
ELISA 0.899 (4.905 to 3.107) 2.044 0.660 0.107 (2.399 to 2.613) 1.279 0.933
Immunoturbidimetry 0.815 (2.627 to 4.258) 1.756 0.643 0.420 (2.566 to 1.727) 1.095 0.702
Intercept 1.609 (0.347 to 2.872) 0.644 0.012 1.204 (0.088 to 2.496) 0.659 0.068
CI, conﬁdence interval, CRP, C-reactive protein, ELISA, enzyme-linked immunosorbent assay, TB, tuberculosis, WHO, World Health Organization.
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screening across the studies. Other APPs, such as AGP, should also
be explored. Although this biomarker could have similar potential
as CRP for triage, we could only ﬁnd one publication that met the
inclusion criteria.
The results of these studies can be modelled in a scenario where
CRP assays were to be used in a high-TB-prevalence setting in a
group of 1000 individuals with symptoms compatible with TB,
where 200 (20%) are typically expected to have a positive TB culture
(conﬁrmed TB). In this scenario, the CRP testwould be followed by a
conﬁrmatory test (e.g. Xpert MTB/RIF) with an estimated 75%
sensitivity and 98% speciﬁcity. In this scenario, an estimated 468
participants will have a positive CRP result (180 truly positive and
288 falsely positive) and 562 would have negative CRP (512 truly
negative and 50 falsely negative). The follow-on Xpert MTB/RIF test
among the 468 patients with positive CRP would correctly identify
135 patients with conﬁrmed TB and six patients with false-positive
results. The combination of CRP followed by Xpert MTB/RIF would
then yield 926 patients (92.6%) correctly classiﬁed, of which 135
would have conﬁrmed TB and 794 would not have conﬁrmed TB
(negative culture). In contrast, testing the same populationwith the
routine Xpert MTB/RIF as the ﬁrst test would result in 150 of 200
patients with TB being classiﬁed as having TB and 784 of 800
participants correctly classiﬁed as not having TB (culture negative).This would result in 934 patients (93.4%) correctly classiﬁed, of
whom 150 would have conﬁrmed TB and 784 would not have
conﬁrmed TB (negative culture). Although the difference between
the two approaches is not statistically signiﬁcant, the screening test
would result in signiﬁcant gains by rapidly identifying 562 patients
with a very low likelihood of having TB, facilitating earlier clinical
management decisions and avoiding having to wait for Xpert MTB/
RIF test results and multiple visits.
Further prospective studies are needed to establish the optimal
assays and thresholds for CRP and/or unstimulated IP-10 for TB
screening and whether their combined use could increase their
performance. Future studies should enrol prospectively consecu-
tive patients with signs and symptoms of presumptive TB under-
going a differential diagnosis. In conclusion, CRP is a promising
marker as a triage test to identify individuals with TB, while the
evidence available for IP-10 is of very low quality. Further pro-
spective studies are warranted for both markers.
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